title: Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
abstract: The evolutionary process from the Arg-Gly-Asp-Phe (RGDF) tetrapeptide to potent orally active anti-platelet agents is presented. The RGD sequence is an important component in the recognition of fibrinogen by its platelet receptor GP IIb-IIIa (integrin alpha IIb beta 3). This work concentrates on the replacement of the Arg-Gly dipeptidyl fragment by an acylated aminobenzamidine. The C-terminal fragment has been replaced by a variety of beta-amino acids, expanding on a previously reported paradigm. The lead compounds showed good potency in an in vitro platelet aggregation assay (dog PRP/ADP). The affinity for the fibrinogen receptor was confirmed in several cases by the ability to inhibit 125I fibrinogen binding to activated human platelets. The ethyl ester prodrug form was tested by oral administration to dogs and monitoring of the anti-platelet effect on ex vivo collagen induced platelet aggregation. From the structural studies reported, the 4-[[(aminoiminomethyl)phenyl]amino]-4-oxobutanoic acid (5) was the best surrogate for the Arg-Gly dipeptide. Several conformationally restricted analogues are also reported which are compatible with the hypothesis of RGD binding to the alpha IIb beta 3 in a turn-extended-turn conformation. The structure-activity relationships described also underline the importance of the beta-amino acid substitution for potency. In particular, the absolute configuration at the beta-carbon was crucial for high affinity. The best acid/ester pairs reported in this study had high potency (acid PRP/ADP IC50 approximately 50 nM) and showed good oral activity in dogs at 5 mg/kg per os (ethyl ester).
authors.affiliation: Thrombosis Research, Searle, Skokie, IL 60077.
authors.forename: P R
authors.initials: PR
authors.lastname: Bovy
authors.forename: F S
authors.initials: FS
authors.lastname: Tjoeng
authors.forename: J G
authors.initials: JG
authors.lastname: Rico
authors.forename: T E
authors.initials: TE
authors.lastname: Rogers
authors.forename: R J
authors.initials: RJ
authors.lastname: Lindmark
authors.forename: J A
authors.initials: JA
authors.lastname: Zablocki
authors.forename: R B
authors.initials: RB
authors.lastname: Garland
authors.forename: D E
authors.initials: DE
authors.lastname: McMackins
authors.forename: H
authors.initials: H
authors.lastname: Dayringer
authors.forename: M V
authors.initials: MV
authors.lastname: Tóth
mesh_terms: D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D001550:Benzamidines / Q000138:chemical synthesis* / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D008297:Male; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D001550:Benzamidines; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; C084961:arginyl-glycyl-aspartyl-phenylalanine; C047981:arginyl-glycyl-aspartic acid